245 related articles for article (PubMed ID: 21129604)
1. Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.
De Vita F; Giuliani F; Silvestris N; Catalano G; Ciardiello F; Orditura M
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S11-5. PubMed ID: 21129604
[TBL] [Abstract][Full Text] [Related]
2. Successful use of Trastuzumab with anthracycline-based chemotherapy followed by trastuzumab maintenance in patients with advanced HER2-positive gastric cancer.
Palacio S; Loaiza-Bonilla A; Kittaneh M; Kyriakopoulos C; Ochoa RE; Escobar M; Arango B; Restrepo MH; Merchan JR; Rocha Lima CM; Hosein PJ
Anticancer Res; 2014 Jan; 34(1):301-6. PubMed ID: 24403478
[TBL] [Abstract][Full Text] [Related]
3. Targeted HER2 treatment in advanced gastric cancer.
Jørgensen JT
Oncology; 2010; 78(1):26-33. PubMed ID: 20185938
[TBL] [Abstract][Full Text] [Related]
4. Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases.
Al-Batran SE; Hozaeel W; Jäger E
Onkologie; 2012; 35(9):505-8. PubMed ID: 23007148
[TBL] [Abstract][Full Text] [Related]
5. Trastuzumab in gastric cancer.
Okines AF; Cunningham D
Eur J Cancer; 2010 Jul; 46(11):1949-59. PubMed ID: 20542421
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models.
Fujimoto-Ouchi K; Sekiguchi F; Yasuno H; Moriya Y; Mori K; Tanaka Y
Cancer Chemother Pharmacol; 2007 May; 59(6):795-805. PubMed ID: 17031648
[TBL] [Abstract][Full Text] [Related]
7. Targeted therapy for gastric cancer--current status.
Kulig J; Kołodziejczyk P; Kulig P; Legutko J
J Oncol Pharm Pract; 2013 Mar; 19(1):75-81. PubMed ID: 22711713
[TBL] [Abstract][Full Text] [Related]
8. How will human epidermal growth factor receptor 2-neu data impact clinical management of gastric cancer?
Lorenzen S; Lordick F
Curr Opin Oncol; 2011 Jul; 23(4):396-402. PubMed ID: 21505336
[TBL] [Abstract][Full Text] [Related]
9. [HER2 and gastric cancer: a novel therapeutic target for trastuzumab].
Bouché O; Penault-Llorca F
Bull Cancer; 2010 Dec; 97(12):1429-40. PubMed ID: 21134821
[TBL] [Abstract][Full Text] [Related]
10. Trastuzumab for gastric cancer.
Meza-Junco J; Au HJ; Sawyer MB
Expert Opin Biol Ther; 2009 Dec; 9(12):1543-51. PubMed ID: 19916733
[TBL] [Abstract][Full Text] [Related]
11. Advances in the management of HER2-positive advanced gastric and gastroesophageal junction cancer.
Bang YJ
J Clin Gastroenterol; 2012 Sep; 46(8):637-48. PubMed ID: 22751336
[TBL] [Abstract][Full Text] [Related]
12. Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm.
Burstein HJ; Harris LN; Marcom PK; Lambert-Falls R; Havlin K; Overmoyer B; Friedlander RJ; Gargiulo J; Strenger R; Vogel CL; Ryan PD; Ellis MJ; Nunes RA; Bunnell CA; Campos SM; Hallor M; Gelman R; Winer EP
J Clin Oncol; 2003 Aug; 21(15):2889-95. PubMed ID: 12885806
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetic analysis of capecitabine and cisplatin in combination with trastuzumab in Japanese patients with advanced HER2-positive gastric cancer.
Satoh T; Omuro Y; Sasaki Y; Hamamoto Y; Boku N; Tamura T; Ohtsu A
Cancer Chemother Pharmacol; 2012 Apr; 69(4):949-55. PubMed ID: 22116464
[TBL] [Abstract][Full Text] [Related]
14. [Human recombinant anti-HER2 monoclonal antibody--a new targeted treatment in breast cancer].
Dank M
Orv Hetil; 2001 Nov; 142(46):2563-8. PubMed ID: 11770175
[TBL] [Abstract][Full Text] [Related]
15. Trastuzumab: a new treatment option for HER2-positive metastatic gastric and gastroesophageal junction cancer.
Lordick F
Future Oncol; 2011 Feb; 7(2):187-99. PubMed ID: 21345138
[TBL] [Abstract][Full Text] [Related]
16. [A complete response of scirrhous gastric carcinoma treated with trastuzumab combination therapy].
Nishi T; Hamamoto Y; Uemoto J; Onodera K; Warita E; Yamanaka Y
Gan To Kagaku Ryoho; 2012 Dec; 39(13):2553-5. PubMed ID: 23235178
[TBL] [Abstract][Full Text] [Related]
17. Trastuzumab plus chemotherapy in gastric cancer overexpressing HER-2 and EGFR: a case report.
Al-Batran SE; Ruppert M; Jäger E
Onkologie; 2011; 34(1-2):42-5. PubMed ID: 21346384
[No Abstract] [Full Text] [Related]
18. Lapatinib in breast cancer: clinical experiences and future perspectives.
Giampaglia M; Chiuri VE; Tinelli A; De Laurentiis M; Silvestris N; Lorusso V
Cancer Treat Rev; 2010 Nov; 36 Suppl 3():S72-9. PubMed ID: 21129615
[TBL] [Abstract][Full Text] [Related]
19. Pathologic complete response after neoadjuvant chemotherapy plus trastuzumab predicts favorable survival in human epidermal growth factor receptor 2-overexpressing breast cancer: results from the TECHNO trial of the AGO and GBG study groups.
Untch M; Fasching PA; Konecny GE; Hasmüller S; Lebeau A; Kreienberg R; Camara O; Müller V; du Bois A; Kühn T; Stickeler E; Harbeck N; Höss C; Kahlert S; Beck T; Fett W; Mehta KM; von Minckwitz G; Loibl S
J Clin Oncol; 2011 Sep; 29(25):3351-7. PubMed ID: 21788566
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab for gastric cancer treatment.
Fujita T
Lancet; 2010 Nov; 376(9754):1735; author reply 1735-6. PubMed ID: 21093641
[No Abstract] [Full Text] [Related]
[Next] [New Search]
